Rituximab biosimilar - Zhejiang Hisun Pharmaceutical

Drug Profile

Rituximab biosimilar - Zhejiang Hisun Pharmaceutical

Alternative Names: HS 006; Recombinant human-mouse chimeric anti-CD20 monoclonal antibody injection - Zhejiang Hisun Pharmaceutical; RHCACD20MA

Latest Information Update: 06 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zhejiang Hisun Pharmaceutical
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma

Most Recent Events

  • 14 Jan 2018 Zhejiang Hisun Pharmaceutical completes a phase II trial in Diffuse large B cell lymphoma (First-line therapy, Combination therapy) (IV) (NCT03485118)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top